Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Grillo-Lopez AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1(1), 1–9 (2000). •• A comprehensive summary of the development and use of rituximab across lymphoma indications.
  Medline CASGoogle Scholar
• 2. ESMO Guidelines Committee. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies). Ann.Oncol. 28(Suppl. 4), iv149–iv152 (2017).
  MedlineGoogle Scholar
• 3. EMA. Assessment report: Rixathon (2017). www.ema.europa.eu/en/documents/assessment-report/rixathon-epar-public-assessment-report_en.pdf
  Google Scholar
• 4. EMA. Truxima EPAR (2016).
  Google Scholar
• 5. Jaeger U. Rituximab biosimilars open new horizons in immunotherapy. ESMO Open 2(3), e000234 (2017).
  MedlineGoogle Scholar
• 6. Jurczak W, Dlugosz Danecka M, Buske C. Rituximab biosimilars for lymphoma in Europe. Expert Opin. Biol. Ther. 19(10), 1045–1056 (2019). •• A concise up-to-date overview of approved and pipeline rituximab biosimilars, including detailed overviews of clinical development programs.
  Medline CASGoogle Scholar
• 7. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 27(5), 495–507 (2013).
  Medline CASGoogle Scholar
• 8. da Silva A, Kronthaler U, Koppenburg V et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk. Lymphoma 55(7), 1609–1617 (2014).
  Medline CASGoogle Scholar
• 9. Jurczak W, Moreira I, Kanakasetty GB et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet. Haematol. 4(8), e350–e361 (2017).
  MedlineGoogle Scholar
• 10. Smolen JS, Choe JY, Prodanovic N et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann. Rheum. Dis. 77(2), 234–240 (2018).
  Medline CASGoogle Scholar
• 11. Tony HP, Kruger K, Cohen SB et al. Brief report: safety and immunogenicity of rituximab biosimilar gp 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res. (Hoboken) 71(1), 88–94 (2019).
  Medline CASGoogle Scholar
• 12. Kim WS, Buske C, Ogura M et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 4(8), e362–e373 (2017).
  MedlineGoogle Scholar
• 13. Ogura M, Sancho JM, Cho SG et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 5(11), e543–e553 (2018).
  MedlineGoogle Scholar
• 14. Yoo DH, Suh CH, Shim SC et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 76(3), 566–570 (2017).
  Medline CASGoogle Scholar
• 15. Yoo DH, Suh CH, Shim SC et al. Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a Phase I randomized controlled trial. BioDrugs 31(4), 357–367 (2017).
  Medline CASGoogle Scholar
• 16. Park W, Bozic-Majstorovic L, Milakovic D et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs 10(6), 934–943 (2018).
  Medline CASGoogle Scholar
• 17. Park W, Suh CH, Shim SC et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: Results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs 31(4), 369–377 (2017).
  Medline CASGoogle Scholar
• 18. Smolen JS, Cohen SB, Tony HP et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 76(9), 1598–1602 (2017).
  Medline CASGoogle Scholar
• 19. Jurczak W, Cohen S, Illidge TM, Silva AD, Amersdorffer J. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. Future Oncol. 15(36), 4223–4234 (2019). • Uses data from the development process for a particular rituximab biosimilar to illustrate the overall principles of biosimilar development.
  CASGoogle Scholar
• 20. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 3(2), 209–217 (2011).
  MedlineGoogle Scholar
• 21. Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 46, 73–79 (2016).
  MedlineGoogle Scholar
• 22. Weise M, Bielsky MC, De Smet K et al. Biosimilars: what clinicians should know. Blood 120(26), 5111–5117 (2012). •• A straightforward introduction to biosimilar concepts, from development to approval.
  Medline CASGoogle Scholar
• 23. Bennett CL, Chen B, Hermanson T et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 15(13), e594–e605 (2014).
  MedlineGoogle Scholar
• 24. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 124(22), 3191–3196 (2014).
  Medline CASGoogle Scholar
• 25. Krause A, Aries PM, Berger S et al. Rituximab in routine care of severe active rheumatoid arthritis: a prospective, non-interventional study in Germany. Z Rheumatol. 78(9), 881–888 (2019).
  Medline CASGoogle Scholar
• 26. Horvat M, Zadnik V, Juznic Setina T et al. Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncol. Lett. 15(3), 3602–3609 (2018).
  MedlineGoogle Scholar
• 27. Reiser M, Dorfel S, Hensel M et al. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. Eur. J. Haematol. 100(5), 455–464 (2018).
  Medline CASGoogle Scholar
• 28. Chaoui D, Choquet S, Sanhes L et al. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. Leuk. Lymphoma 58(6), 1366–1375 (2017).
  Medline CASGoogle Scholar
• 29. Wendler J, Burmester GR, Sorensen H et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res. Ther. 16(2), R80 (2014).
  MedlineGoogle Scholar
• 30. Cziraky M, Pollock M. Real-world evidence studies (2015). www.appliedclinicaltrialsonline.com/real-world-evidence-studies
  Google Scholar
• 31. Christel M. “Evidence” trail elusive (2014) www.appliedclinicaltrialsonline.com/evidence-trail-elusive-0
  Google Scholar
• 32. Franceschetti A, Baskett A, Baynton E, Baldock D, Karki C. Comparative analysis of biosimilar rituximab usage in treating non-Hodgkin lymphoma and rheumatoid arthritis: results from a multi-country study in Europe. Presented at ISPOR EU, Barcelona, Spain (2018). https://tools.ispor.org/research_pdfs/60/pdffiles/PHP113.pdf
  Google Scholar
• 33. Wiland P, Batko B, Brzosko M et al. Biosimilar switching - current state of knowledge. Reumatologia 56(4), 234–242 (2018).
  MedlineGoogle Scholar
• 34. EMA. Biosimilars in the EU (2019) www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
  Google Scholar
• 35. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs 78(4), 463–478 (2018).
  Medline CASGoogle Scholar
• 36. Wilking N, Lopez G, Meier K, Simoens S, van Harten W, Vulto A. Can we continue to afford access to cancer treatment? Eur. Oncol. Haematol. 13(2), 114–119 (2017). • A concise summary of the growing issues with maintaining the sustainability of cancer treatment.
  Google Scholar
• 37. Simoens S, van Harten W, Lopez G, Vulto A, Meier K, Wilking N. What happens when the cost of cancer care becomes unsustainable? Eur. Oncol. Haematol. 13(2), 108–113 (2017).
  Google Scholar
• 38. Lopez G, Vulto A, Wilking N, van Harten W, Meier K, Simoens S. Potential solutions for sustaining the costs of cancer drugs. Eur. Oncol. Haematol. 13(2), 102–107 (2017). • An elegant overview of potential solutions to issues of sustainability in cancer care, of which biosimilars represent one avenue.
  Google Scholar
• 39. McBride A, Balu S, Campbell K, MacDonald K, Abraham I. Subcutaneous versus intravenous rituximab in non-hodgkin lymphoma treated with R-CHOP: economic modeling for the US (ASH 2018 abstract). Blood 132, 4776 (2018).
  Google Scholar
• 40. Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 39(7), 3971–3973 (2019).
  MedlineGoogle Scholar